Surge in Number of Clinical Trials and a Presence of Key Players has Propelled the Growth of the Clinical Trial Supplies Market in the North America Region!

North America held a dominant share of the market in 2021. North America’s dominance of the global clinical trial supply market is due to the growing number of clinical trials worldwide, the advancement of technology, government funding, and the increasing prevalence of diseases. Major CROs and biopharmaceutical companies have their headquarters in this region due to the high number of large-scale pharmaceutical R&D clinical trials conducted here. The region also has effective regulations in place for clinical trials, such as the use of electronic records and signatures, the protection of human subjects, and good clinical practices for non-clinical laboratory studies, which facilitates the overall clinical trial process.

Access sample report (including graphs, charts, and figures): https://univdatos.com/report/clinical-trial-supplies-market/get-a-free-sample-form.php?product_id=40687

Further, the North America Clinical Trial Supplies Market is expected to grow at a strong CAGR of 6.5% during the forecast period (2022-20230). According to a survey conducted in 2021, around 60% of clinical trials in phase 2 are outsourced, and North America has the highest number of projects in this phase. This trend has led to a high investment in R&D by industry and other out-of-industry sponsors. In addition, the concentration of pharmaceutical leaders in the region has driven the development of innovative combinations of approved and novel treatments, which has resulted in a high number of phase 2 trial studies. The high prevalence of cancer in the United States is another factor driving the clinical trial supply market in North America. In 2022, Cancer.Org reported that there were 609,360 new cancer cases in the United States, a 0.12% increase from the previous year.

• Revenue (2020-2030)- USD Mn

For a detailed analysis of the Global Clinical Trial Supplies Market browse through ;https://univdatos.com/report/clinical-trial-supplies-market/

Based on the phase, the market is segmented into phase-I, phase-II, phase-III, and phase-IV. The phase-I is anticipated to witness high CAGR during the forecast period. The COVID-19 pandemic has led to a significant increase in the number of clinical trials for its treatment and prevention, particularly in the phase I trials. For instance, in March 2021, Pfizer Inc. initiated phase-I clinical trial to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.

By services, the market is categorized in manufacturing, storage & distribution, supply chain management, and comparator sourcing. The supply chain management held a significant share of the market in 2021. The supply chain management segment is a critical component of the clinical trial supplies market, as it plays a key role in ensuring the success of clinical trials. The efficient management of supplies and materials is essential to ensure that clinical trials are conducted in a timely and cost-effective manner, and that the safety and well-being of trial participants are protected.

Based on end use, the market is categorized into pharmaceutical, biologics, medical device, and others. The biologics category is anticipated to grow with a significant CAGR during the forecast period. In recent years, the use of biologics such as hormones, blood products, vaccines, genes, insulin, and monoclonal antibody (mAb) products has increased as advanced therapies for the treatment of diseases like Crohn’s disease, rheumatoid arthritis, and other autoimmune diseases. The increased widespread use has led to significant growth in the biologics market over the forecast period. The rapid increase in the number of cancer cases is also driving the growth of the biologics market. Biologics therapy is becoming increasingly popular as it uses the body’s immune systems and abilities to fight cancer or heal healthy tissue after treatment. For instance, the Journal of Global Oncology reported that biologics accounted for an overall 55% of the total expenditure on antineoplastic drugs in the healthcare system. As a result, the higher incidence of cancer cases is expected to drive the growth of the biologics market.

Based on therapeutic use, the market is categorized into oncology, CNS, cardiovascular, infectious disease, metabolic disorders, dermatology, ophthalmology, and others. The oncology segment held a dominant share of the market in 2021. The oncology segment has a large and active R&D pipeline, with many new drugs and treatments in development. This pipeline includes a wide range of therapies, including targeted therapies, immunotherapies, and others. The development of new drugs and treatments is expected to drive the growth of the oncology segment in the clinical trial supplies market.

Global Clinical Trial Supplies Market Segmentation

Market Insight, by Phase

• Phase-I
• Phase-II
• Phase-III
• Phase-IV

Market Insights, by Services

• Manufacturing
• Storage & Distribution
• Supply Chain Management
• Comparator Sourcing

Market Insights, by End Use

• Pharmaceutical
• Biologics
• Medical Device
• Others

Market Insights, by Therapeutic Use

• Oncology
• CNS
• Cardiovascular
• Infectious Disease
• Metabolic Disorders
• Dermatology
• Opthalmology
• Others

Market Insight, by Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• North America
  • China
  • Japan
  • India
  • Rest of North America
• Rest of the World

Top Company Profiles

• Thermo Fisher Scientific
• Catalent, Inc.
• Parexel
• Almac Group
• Marken
• Piramal Pharma Solutions
• Inizio
• Recipharm
• Myonex
• Rubicon Research Pvt. Ltd.